B. S. Graham

An optimized messenger RNA vaccine candidate protects non-human primates from Zika virus infection

This study compares two ZIKV mRNA vaccines, showing that mRNA-1893 provides complete protection at a lower dose than mRNA-1325 in non-human primates.

A Multivalent Polyomavirus Vaccine Elicits Durable Neutralizing Antibody Responses in Macaques

This study shows a multivalent polyomavirus vaccine induces high, durable neutralizing antibodies in macaques without adverse effects.

Vaccine-elicitation of cross-group neutralizing protective antibodies to influenza A viruses

This study shows that co-immunization with stem immunogens from group 1 and 2 influenza A HAs elicits cross-group neutralizing antibodies and protective immunity in multiple animal models.

Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway

This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.

Structure-based design of stabilized recombinant influenza neuraminidase tetramers

This study designs stabilized recombinant influenza neuraminidase tetramers by uncovering structural principles and improving thermal stability and antibody affinity.

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants

This study assesses the durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants over seven months, finding persistent but reduced binding and functional responses.

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

This study assesses neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant in convalescent and vaccinated individuals, finding it is 6.8-fold more resistant but still neutralizable.

Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice

This study evaluates updated SARS-CoV-2 mRNA vaccines in mice, showing that mRNA-1273.351 boosts neutralization against B.1.351 and mRNA-1273.211 provides broad cross-variant protection.

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants

The paper identifies ultrapotent antibodies from convalescent donors that neutralize SARS-CoV-2 variants and reduce escape mutant generation.

mRNA-1273 efficacy in a severe COVID-19 model: attenuated activation of pulmonary immune cells after challenge

This study evaluates mRNA-1273 vaccine efficacy in hamsters, showing reduced pulmonary immune activation and improved disease outcomes after prime-boost vaccination.

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

This study evaluates the neutralization resistance of SARS-CoV-2 variants B.1.1.7 and B.1.351 to monoclonal antibodies and sera, finding increased resistance in B.1.351.

Human antibody immune responses are personalized by selective removal of MHC-II peptide epitopes

The paper shows that MHC-II epitope removal from BCRs correlates with antibody development, T cell help, and long-term serum antibody secretion.

Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes

The paper develops biotin-labeled SARS-CoV-2 spike molecular probes using structure-based design and purification methods, achieving high yields and enabling antibody characterization.

A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone

This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.

Broad sarbecovirus neutralizing antibodies define a key site of vulnerability on the SARS-CoV-2 spike protein

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

Validation of a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance

This study optimizes and validates a SARS-CoV-2 spike ELISA for use in contact investigations and serosurveillance, demonstrating its specificity and sensitivity.

Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies

This study isolates and characterizes VHH antibodies that neutralize MERS-CoV, SARS-CoV-1, and SARS-CoV-2 by blocking receptor binding, with structural insights into their epitopes and cross-reactivity.

Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation

The paper determines the cryo-EM structure of the 2019-nCoV Spike protein in the prefusion conformation and shows higher ACE2 binding affinity compared to SARS-CoV.

A comprehensive influenza reporter virus panel for high-throughput deep profiling of neutralizing antibodies

The paper develops a fluorescent reporter virus panel to enable high-throughput neutralization profiling of influenza antibodies without requiring high-containment labs.

Trypsin treatment unlocks barrier for zoonotic coronaviruses infection

This study shows that proteolytic cleavage, not receptor binding, is the main barrier for two MERS-like bat coronaviruses to infect human cells, and that trypsin treatment can overcome this barrier.

Design of nanoparticulate group 2 influenza hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages

This study designs nanoparticle-based influenza HA stem antigens that activate unmutated B cell receptors of broadly neutralizing antibodies, potentially enabling cross-group immunity.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen

This study demonstrates that a computationally designed epitope-focused immunogen enhances subdominant neutralizing antibody responses against RSV.

Receptor binding and proteolysis do not induce large conformational changes in the SARS-CoV spike

This study uses cryo-EM to show that ACE2 binding and trypsin cleavage of SARS-CoV spike protein do not cause major conformational changes or expose the S2 cleavage site.